ARS Pharmaceuticals, Inc. (SPRY)
ARS Pharmaceuticals, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
ARS Pharmaceuticals, Inc. (SPRY) is a Biotechnology company based in US with a market capitalization of $631.6M. Revenue declined 5.5% year-over-year and free cash flow was negative at -$171.2M. This page tracks SPRY's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 155 employees · IPO Dec 4, 2020
Valuation
Valuation & price
$7.42as of May 17, 2026· -59.5% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
5.53
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$631.6M
Market cap
-5.5%
Revenue growth (YoY)
75.8%
Gross margin
-$171.2M
Free cash flow (USD)
-$148M
Net debt
Net cash position
1.7%
Share dilution
0/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2018 → 2025
Free cash flow by year
2018 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last reported: May 15, 2026 (EPS $-0.61)
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
Questions
Frequently asked questions
What is ARS Pharmaceuticals, Inc.'s market cap?
ARS Pharmaceuticals, Inc. (SPRY) has a market capitalization of $631.6M.
What is SPRY's P/E ratio?
A meaningful P/E ratio is not available for SPRY — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is SPRY's price-to-book (P/B) ratio?
SPRY trades at 5.53 times book value per share.
When did ARS Pharmaceuticals, Inc. last report earnings?
SPRY last reported earnings on May 15, 2026; the next date is not yet scheduled.
Are insiders buying SPRY stock?
SEC Form 4 filings show no open-market insider buys at ARS Pharmaceuticals, Inc. in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.